Chemoembolization and bland embolization: a critical appraisal
1Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, MO 63110, USA. befelera@slu.edu
Abstract:
Hepatocellular carcinoma is a major cause of cancer-related mortality worldwide, and most patients are not candidates for potentially curative treatment. Bland and chemoembolization are palliative options for hepatocellular carcinoma (HCC) that have been evaluated in controlled trials. Chemoembolization and perhaps bland embolization used as primary treatment for HCC in selected patients are effective at prolonging survival. The role of these therapies before surgical resection, liver transplantation, or in combination with local ablative therapy is controversial and yet unproven.
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...